Mirtazapine Dosing for Akathisia
For antipsychotic-induced akathisia, start mirtazapine at 15 mg once daily at bedtime, which is the evidence-based dose that has demonstrated efficacy in randomized controlled trials.
Evidence-Based Dosing
The strongest evidence supports 15 mg/day as the standard dose for treating antipsychotic-induced akathisia 1, 2, 3. This recommendation is based on:
- A 2024 network meta-analysis of 15 RCTs (492 participants) found mirtazapine 15 mg/day for ≥5 days showed the greatest efficacy among all treatments (SMD -1.20; 95% CI -1.83 to -0.58) 1
- A landmark 2006 double-blind RCT demonstrated 15 mg mirtazapine was superior to placebo with 43.3% response rate versus 6.7% placebo (odds ratio 10.7) 2
- Meta-analysis showed number needed to treat (NNT) of 4 for response and 5 for complete remission with 15 mg dosing 3
Alternative Lower Dose Option
7.5 mg once daily may be considered for patients concerned about tolerability, though evidence is more limited:
- A 2018 retrospective study of 12 patients showed 7.5 mg reduced akathisia severity with 41.6% response rate and better tolerability (no drowsiness or appetite increase reported) 4
- This lower dose may be particularly useful when sedation or weight gain are concerns
- However, the 7.5 mg dose has not been validated in large-scale controlled trials 4
Practical Implementation
Timing and administration:
- Administer at bedtime to leverage sedating properties 5
- Continue for at least 5-7 days before assessing response 1, 2
- Monitor using Barnes Akathisia Rating Scale (BARS) - response defined as ≥2 point reduction 2
Dose adjustments:
- If inadequate response after 1-2 weeks at 15 mg, the FDA-approved maximum is 45 mg/day 5
- However, akathisia studies have not evaluated doses above 15 mg
- Do not increase dose intervals faster than 1-2 weeks 5
Important Clinical Considerations
Advantages over alternatives:
- Mirtazapine 15 mg showed comparable efficacy to propranolol 80 mg but superior tolerability 2
- Unlike propranolol, mirtazapine caused no clinically significant hypotension or bradycardia requiring discontinuation 2
- Particularly effective for aripiprazole-induced akathisia 4
Monitoring requirements:
- Watch for somnolence (54% incidence in depression trials) 5
- Monitor weight (7.5% gained ≥7% body weight in trials) 5
- Assess for serotonin syndrome if combining with other serotonergic agents 5
Contraindications and cautions:
- Do not use within 14 days of MAOI antidepressants 5
- Reduce dose if co-administered with strong CYP3A4 inhibitors (ketoconazole, clarithromycin) or cimetidine 5
- Screen for bipolar disorder before initiating, as mirtazapine may precipitate mania 5
When Mirtazapine Fails
If akathisia persists after adequate trial of mirtazapine 15 mg:
- Consider propranolol 20-80 mg/day (though less well-tolerated) 1, 2
- Vitamin B6 600-1200 mg/day showed efficacy (SMD -0.92) 1
- Biperiden 6 mg/day is an anticholinergic alternative 1
- Benzodiazepines (clonazepam) or gabapentinoids may provide symptomatic relief 6, 7
The evidence clearly positions 15 mg once daily at bedtime as the optimal starting dose, with 7.5 mg reserved for patients requiring enhanced tolerability at the potential cost of reduced efficacy.